Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

10 stocks we like ... for the development of new drugs. At the time, GSK made a $300 million equity investment in 23andMe, which is more than the amount Regeneron could end up paying for the ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals ... building the world's greatest ...

This typically results in pricing pressure and a gradual loss of market share for branded drugs. Regeneron's Eylea HD ... In an early-stage trial, 10 of 11 children showed improvements in hearing ...

There is no pause button to stop the world from spinning ... a version of the SARS-CoV-2 virus that circulated then. Regeneron Pharmaceutical reached an agreement to buy the consumer genetics ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

His innovation reduces the cost per gram from $75.00 to just $12.00, and the production time per batch from 9 days to just 5.

We recently published a list of 10 Worst Blue Chip Stocks ... among others. Based on Regeneron’s track record of success discovering and developing new drugs, we are optimistic the pipeline ...

Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be involved in different ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...